olivLaw · US equity research
Takeda Pharmaceutical Company Limited TAK
Pharmaceutical Preparations · SIC 2834
Takeda is a global research-driven biopharmaceutical company focused on gastrointestinal and inflammation, neuroscience, oncology, and plasma-derived therapies. In fiscal 2026 revenue reached 4505.7 billion JPY, and the company is in a transition period, with new launches and late-stage pipeline programs set against loss of exclusivity on important products.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Takeda Pharmaceutical Company Limited (TAK) stock was 21.06 USD (+1.49% on the day), with beta 0.16, 52-week range 13.59–21.06 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 71.3
- overbought (≥ 70)
- Bollinger (20, 2)
- 18.27 – 21.45
- in the upper half of the band · %B 0.88 · band width 16.0%
- SMA 50 / 200
- 19.00 / 17.60
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.60 / 0.52
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +18.2% | −1.1% | +19.3 pp | — |
| 3 months | +26.0% | −0.5% | +26.4 pp | — |
| 6 months | +26.0% | +4.4% | +21.6 pp | — |
| Year to date | +35.1% | +12.3% | +22.8 pp | — |
| 1 year | +55.3% | +13.5% | +41.8 pp | — |
| 3 years | +50.3% | +76.4% | −26.1 pp | — |
| 5 years | +47.8% | +63.7% | −15.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,770.5 bn | 2,097.2 bn | 3,291.2 bn | 3,197.8 bn | 3,569.0 bn | 4,027.5 bn | 4,263.8 bn | 4,581.6 bn |
| Revenue YoY | +2.2% | +18.5% | +56.9% | −2.8% | +11.6% | +12.8% | +5.9% | +7.5% |
| Net income | 186.9 bn | 135.2 bn | 44.2 bn | 376.0 bn | 230.1 bn | 317.0 bn | 144.1 bn | 107.9 bn |
| Net income YoY | +62.6% | −27.7% | −67.3% | +749.9% | −38.8% | +37.8% | −54.6% | −25.1% |
| Diluted EPS | 237.56 | 139.82 | 28.25 | 238.96 | 145.87 | 201.94 | 91.16 | 67.23 |
| Diluted EPS YoY | +62.4% | −41.1% | −79.8% | +745.9% | −39.0% | +38.4% | −54.9% | −26.3% |
| net % | 10.6% | 6.4% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% |
| Free cash flow | 310.8 bn | 250.8 bn | 542.7 bn | 899.7 bn | 999.9 bn | 836.5 bn | 540.9 bn | 856.4 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Mar 2025
- Cash
- 385.1 bn JPY
- Financial debt
- 3,966.3 bn JPY
- Net debt
- 3,581.2 bn JPY
- Equity
- 6,936.0 bn JPY
- Total assets
- 14,248.3 bn JPY
- Debt / equity
- 0.57x
- Current ratio
- 1.01x
- ROE
- 1.5%
- ROA
- 0.7%
- FCF margin
- 18.7%
Financial statements (source on every figure)
Revenue and net income (JPY)
Margins
Income statement · JPY
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 3,291.2 bn | 3,197.8 bn | 3,569.0 bn | 4,027.5 bn | 4,263.8 bn | 4,581.6 bn | SEC (XBRL)· 25 Jun 2025verified |
| Cost of revenue | 1,089.8 bn | 994.3 bn | 1,106.8 bn | 1,244.1 bn | 1,426.7 bn | 1,580.2 bn | SEC (XBRL)· 25 Jun 2025verified |
| Gross profit | 2,201.4 bn ≈ | 2,203.5 bn ≈ | 2,462.2 bn ≈ | 2,783.4 bn ≈ | 2,837.1 bn ≈ | 3,001.3 bn ≈ | SEC (XBRL)· 25 Jun 2025derived |
| Research & development | 492.4 bn | 455.8 bn | 526.1 bn | 633.3 bn | 729.9 bn | 730.2 bn | SEC (XBRL)· 25 Jun 2025verified |
| Operating income | 100.4 bn | 509.3 bn | 460.8 bn | 490.5 bn | 214.1 bn | 342.6 bn | SEC (XBRL)· 25 Jun 2025verified |
| Depreciation & amortisation | 583.6 bn | 559.7 bn | 583.2 bn | 664.4 bn | 728.0 bn | 761.4 bn | SEC (XBRL)· 25 Jun 2025verified |
| EBITDA | 684.1 bn ≈ | 1,068.9 bn ≈ | 1,044.0 bn ≈ | 1,154.9 bn ≈ | 942.1 bn ≈ | 1,104.0 bn ≈ | SEC (XBRL)· 25 Jun 2025derived |
| Interest expense | 165.0 bn | 248.6 bn | 166.6 bn | 169.7 bn | 219.9 bn | 210.1 bn | SEC (XBRL)· 25 Jun 2025verified |
| Pre-tax income | -60.8 bn | 366.2 bn | 302.6 bn | 375.1 bn | 52.8 bn | 175.1 bn | SEC (XBRL)· 25 Jun 2025verified |
| Income tax | -105.0 bn | -9.9 bn | 72.4 bn | 58.1 bn | -91.4 bn | 66.9 bn | SEC (XBRL)· 25 Jun 2025verified |
| Net income | 44.2 bn | 376.0 bn | 230.1 bn | 317.0 bn | 144.1 bn | 107.9 bn | SEC (XBRL)· 25 Jun 2025verified |
| Diluted EPS | 28.25 | 238.96 | 145.87 | 201.94 | 91.16 | 67.23 | SEC (XBRL)· 25 Jun 2025verified |
| Weighted average diluted shares | 1.6 bn | 1.6 bn | 1.6 bn | 1.6 bn | 1.6 bn | 1.6 bn | SEC (XBRL)· 25 Jun 2025verified |
| Dividend per share | 181.40 | — | — | — | — | — | SEC (XBRL)· 24 Jun 2020derived |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · JPY
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 637.6 bn | 966.2 bn | 849.7 bn | 533.5 bn | 457.8 bn | 385.1 bn | SEC (XBRL)· 25 Jun 2025verified |
| Receivables | 757.0 bn | 783.1 bn | 696.6 bn | 649.4 bn | 668.4 bn | 709.5 bn | SEC (XBRL)· 25 Jun 2025verified |
| Inventories | 759.6 bn | 753.9 bn | 853.2 bn | 986.5 bn | 1,209.9 bn | 1,217.3 bn | SEC (XBRL)· 25 Jun 2025verified |
| Current assets | 2,469.4 bn | 2,712.9 bn | 2,593.6 bn | 2,398.0 bn | 2,558.6 bn | 2,521.2 bn | SEC (XBRL)· 25 Jun 2025verified |
| Property, plant & equipment, net | 1,386.4 bn | 1,453.9 bn | 1,582.8 bn | 1,691.2 bn | — | — | SEC (XBRL)· 28 Jun 2023verified |
| Goodwill | 4,012.5 bn | 4,033.9 bn | 4,407.7 bn | 4,790.7 bn | 5,410.1 bn | 5,324.4 bn | SEC (XBRL)· 25 Jun 2025verified |
| Intangibles (excl. goodwill) | 4,171.4 bn | 3,909.1 bn | 3,818.5 bn | 4,269.7 bn | 4,274.7 bn | 3,631.6 bn | SEC (XBRL)· 25 Jun 2025verified |
| Total assets | 12,821.1 bn | 12,912.3 bn | 13,178.0 bn | 13,957.8 bn | 15,108.8 bn | 14,248.3 bn | SEC (XBRL)· 25 Jun 2025verified |
| Accounts payable | 318.8 bn | 343.8 bn | 516.3 bn | 649.2 bn | 547.5 bn | 475.5 bn | SEC (XBRL)· 25 Jun 2025verified |
| Long-term debt | 4,506.5 bn | 4,613.2 bn | 4,141.4 bn | 4,042.7 bn | 4,476.5 bn | 3,966.3 bn | SEC (XBRL)· 25 Jun 2025verified |
| Current liabilities | 2,175.9 bn | 1,773.2 bn | 2,145.7 bn | 2,481.9 bn | 2,313.1 bn | 2,506.5 bn | SEC (XBRL)· 25 Jun 2025verified |
| Total liabilities | 8,093.6 bn | 7,735.1 bn | 7,494.5 bn | 7,603.1 bn | 7,834.8 bn | 7,312.4 bn | SEC (XBRL)· 25 Jun 2025verified |
| Equity | 4,727.5 bn | 5,177.2 bn | 5,685.7 bn | 6,354.7 bn | 7,274.0 bn | 6,936.0 bn | SEC (XBRL)· 25 Jun 2025verified |
| Shares outstanding at year end | 1.6 bn | — | — | — | — | — | SEC (XBRL)· 24 Jun 2020verified |
- 2023
- 4,269.7 bn
- 2024
- 4,274.7 bn
- 2025
- 3,631.6 bn
SEC (XBRL)· 25 Jun 2025verified
Cash flow · JPY
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 669.8 bn | 1,010.9 bn | 1,123.1 bn | 977.2 bn | 716.3 bn | 1,057.2 bn | SEC (XBRL)· 25 Jun 2025verified |
| Capex | 127.1 bn | 111.2 bn | 123.3 bn | 140.7 bn | 175.4 bn | 200.8 bn | SEC (XBRL)· 25 Jun 2025verified |
| Free cash flow | 542.7 bn ≈ | 899.7 bn ≈ | 999.9 bn ≈ | 836.5 bn ≈ | 540.9 bn ≈ | 856.4 bn ≈ | SEC (XBRL)· 25 Jun 2025derived |
| Investing cash flow | 292.1 bn | 393.5 bn | -198.1 bn | -607.1 bn | -463.9 bn | -367.1 bn | SEC (XBRL)· 25 Jun 2025verified |
| Financing cash flow | -1,005.2 bn | -1,088.4 bn | -1,070.3 bn | -709.1 bn | -354.4 bn | -751.4 bn | SEC (XBRL)· 25 Jun 2025verified |
| Dividends paid | 282.6 bn | 283.4 bn | 283.7 bn | 279.4 bn | 287.2 bn | 302.5 bn | SEC (XBRL)· 25 Jun 2025verified |
| Share repurchases | 3.7 bn | 2.1 bn | 77.5 bn | 26.9 bn | 2.3 bn | 51.9 bn | SEC (XBRL)· 25 Jun 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 32 / 100
A scoring methodology on indicators and valuation, not investment advice.
score < 40
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
- Balance sheet15
- Growth36
- Returns100
- Quality32
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Unattractive profile · Score 32/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 1.9% | 0 (on a fixed band) | 16% |
| Net margin · Quality | 2.4% | 16 (on a fixed band) | 10% |
| FCF conversion · Quality | 793.5% | 100 (on a fixed band) | 10% |
| Revenue CAGR 3Y · Growth | 8.7% | 72 (on a fixed band) | 13% |
| EPS CAGR 3Y · Growth | -22.8% | 0 (on a fixed band) | 13% |
| Net debt / EBITDA · Balance sheet | 3.2x | 22 (on a fixed band) | 16% |
| Interest coverage · Balance sheet | 1.6x | 2 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 1.0x | 17 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | 35.3% | 100 (on a fixed band) | 6% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet15/100 · 3/3 factors with a value
- Growth36/100 · 2/2 factors with a value
- Quality32/100 · 3/3 factors with a value
- Returns· partial100/100 · 1/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Takeda Pharmaceutical Company Limited (TAK). Latest full fiscal year: 2025; data up to 2025-03-31.
Figures computed from the financial statements: revenue 4,581.6 bn JPY in 2025; YoY growth 7.5%; net margin 2.4%; ROE 1.5%; net debt/EBITDA 3.2x.
The estimated value range is 1,779.47–2,198.17 JPY per share (median of 1 methods, agreement: single method); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 32/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns, valuation. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 793.5%
- Revenue CAGR 3Y: 8.7%
- Payout ratio (FCF): 35.3%
What contradicts it
- ROIC: 1.9%
- Net margin: 2.4%
- EPS CAGR 3Y: -22.8%
- Net debt / EBITDA: 3.2x
- Interest coverage: 1.6x
- Current ratio: 1.0x
Not assessed (insufficient data or a ratio without meaning): P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions).
Versus the vertical median
Not enough comparable companies with data for an average.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 17 Jun 2026; since then the company filed 6-K (29 Oct 2026), 6-K (14 Sept 2026), 6-K (31 Aug 2026), 6-K (06 Aug 2026), 6-K (30 Jul 2026).
In brief
Takeda is a global research-driven biopharmaceutical company focused on gastrointestinal and inflammation, neuroscience, oncology, and plasma-derived therapies. In fiscal 2026 revenue reached 4505.7 billion JPY, and the company is in a transition period, with new launches and late-stage pipeline programs set against loss of exclusivity on important products.
SWOT
Strengths
- The company has a geographically diversified base and a strong plasma-derived immunology portfolio, backed by a large collection network.
- The R&D engine combines internal resources with external partnerships and covers several therapeutic modalities.
- Products such as ENTYVIO and TAKHZYRO show solid growth and hold important positions in key markets.
Weaknesses
- A significant share of revenue depends on a small number of products, which makes the company sensitive to loss of exclusivity.
- Operating profit in fiscal 2026 was very small relative to revenue, which points to margin pressure.
- Exposure to currency fluctuations, given the large share of revenue from outside Japan, can affect reported results.
Opportunities
- New launches such as zasocitinib, oveporexton and rusfertide could open new revenue sources.
- Higher plasma collection volume and network optimization could support growth in immunology products.
- Digitalization and artificial intelligence could speed up drug discovery and streamline operations.
Threats
- Generic and biosimilar competition could further reduce sales of products whose patent protection has expired.
- Price pressure from insurers and pharmacy benefit managers could limit revenue.
- Regulatory changes and rising compliance requirements could prolong approvals and increase costs.
Risks
- Clinical trial failurehigh
Drug development is costly and uncertain, and studies can fail even at late stages, which could lead to discontinuation of important programs.
- Loss of exclusivityhigh
Patent expiry could quickly reduce sales of key products if new launches do not offset the decline.
- Pricing pressuremedium
Price control schemes and mandatory discounts in the U.S. and Europe could affect margins and revenue.
- Plasma supplymedium
Plasma-derived production depends on collected raw material, and difficulties in acquisition or delayed approval of new centers could affect output.
- Regulatory framework and investigationsmedium
Legislative changes and ongoing investigations could create defense costs, fines or restrictions on reimbursement access.
Investment thesis
What would need to be true (bull case)
- If zasocitinib, oveporexton and rusfertide reach commercial launch, the company could diversify revenue beyond mature products.
- Growth in plasma-derived immunology products and collection volume could support revenue over the medium term.
- A diversified portfolio and global presence could cushion the impact of a problem in any single market.
What would break the thesis
- Generic competition for important products could reduce revenue faster than new launches can compensate.
- Operating profit that is very small relative to revenue could limit investment capacity and shareholder returns.
- If studies or approvals are delayed, expected launches could postpone revenue growth.
What to watch
- FDA submission of zasocitinib and any decision on Priority Review2026
- Trend of sales for products facing generic competition, particularly VYVANSE/ELVANSE and TRINTELLIXQ1 2027
- Commercial launches of oveporexton and rusfertide after expected approvals2027
- New reporting structure with New Launches and Core In-line Brands categories starting in fiscal 2027next 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 17 Jun 2026; since then the company filed 6-K (29 Oct 2026), 6-K (14 Sept 2026), 6-K (31 Aug 2026), 6-K (06 Aug 2026), 6-K (30 Jul 2026).
The business
Takeda describes itself as a global biopharmaceutical company focused on discovering and delivering life-transforming treatments in three core therapeutic areas: gastrointestinal and inflammation, neuroscience and oncology, along with plasma-derived therapies and vaccines 1. The company has a presence in about 80 countries and regions, major research centers in Japan and the United States, and approximately 47000 employees worldwide 1. For the fiscal year ended March 31, 2026, the company operated as a single operating segment and reported operating profit of 6.2 billion JPY 1.
Its business model combines an internal R&D engine with external partners to access different modalities such as biologics and small molecules 1. The company is pursuing efficiency through digitalization, automation and AI, and in March 2026 its Board approved further steps including streamlining of corporate functions 1. Capital is directed toward investment in the business, maintaining an investment grade credit rating and returning cash to shareholders 1.
Past acquisitions such as Millennium Pharmaceuticals, Nycomed and Shire extended its presence in oncology, Europe, emerging markets and rare diseases 1. In recent fiscal years the company divested assets in non-core areas and now focuses on strategic pipeline investment, new product launches, efficiency improvements and shareholder returns 1.
Segments
Gastrointestinal and inflammation
The leading product is ENTYVIO, for ulcerative colitis and Crohn's disease, which was the top selling product in fiscal 2026 with revenue of 958.0 billion JPY 1. Other products in this area include GATTEX/REVESTIVE, TAKECAB/VOCINTI and EOHILIA for eosinophilic esophagitis 1.
Rare diseases and plasma-derived therapies
TAKHZYRO, for prevention of hereditary angioedema attacks, generated 223.9 billion JPY, while the plasma immunology portfolio including GAMMAGARD LIQUID/KIOVIG, HYQVIA and CUVITRU delivered 790.6 billion JPY 1. This segment depends on a plasma donation network that exceeds 270 centers in the U.S. and EU 1.
Oncology and neuroscience
The company reported that zasocitinib, an oral TYK2 inhibitor for psoriasis and other immune-mediated diseases, met its primary endpoints in two Phase 3 studies, with an FDA submission targeted in calendar year 2026 1. The pipeline also includes rusfertide and oveporexton, for which NDAs were submitted in the U.S. with Priority Review granted 1.
Market context
Takeda operates in a global medicines market where pricing, reimbursement and generic competition are constant pressures. More than 90 percent of revenue comes from outside Japan, especially the United States, Europe and China 1. The regulatory framework is shifting, and the EU pharmaceutical reform, with potentially shorter exclusivity periods, could change market conditions for new products 1.
In the U.S. and European markets, distributors and pharmacy benefit managers press on prices, and mandatory discounts under the 340B program and the Inflation Reduction Act could reduce revenue from some products 1. Revenue is also exposed to currency movements, particularly against the U.S. dollar and the euro 1.
Trends
- Loss of exclusivity on mature productsheadwind
Generic competition reduced VYVANSE/ELVANSE sales to 203.2 billion JPY in fiscal 2026, and the company expects these declines to continue in fiscal 2027, and anticipates generic competition for TRINTELLIX after December 2026 1.
- New launches and pipeline expansiontailwind
Oveporexton, rusfertide and zasocitinib could be launched commercially in 2026 and 2027, which could offset declines in mature products 1.
- Growth in plasma collectiontailwind
Plasma collection volume grew in fiscal 2026, supported by new donation centers and network optimization, which supports the plasma-derived immunology products 1.
- Currency effects and price pressuremixed
A weaker yen had a positive effect on revenue in recent years, but a stronger yen could reduce yen-denominated revenue, and drug price pressure remains an issue 1.
Competitive position
Takeda competes on efficacy, safety and price, and products under patent protection face generic or biosimilar competition once protection expires 1. The company notes that some of its principal products face considerable competition following expiration of intellectual property protection 1.
In plasma-derived immunology, rare diseases and gastroenterology, Takeda competes with other companies developing similar or alternative treatments. The provided sources do not name competitors, so the list below is limited to what the filing explicitly mentions 1.
- Generic and biosimilar manufacturers
They reduced sales of mature Takeda products such as VYVANSE/ELVANSE and AZILVA after patent protection expired 1.
- Companies with rival rare disease treatments
For products such as TAKHZYRO and ELAPRASE, competition depends on efficacy, market access and reimbursement, without a named competitor in the source 1.
- Plasma immunology competitors
Plasma collection and fractionation compete with other immunoglobulin producers, as the raw material risks in the filing suggest 1.
- TYK2 inhibitor developers in psoriasis
Zasocitinib enters a treatment area where other therapeutic agents exist, but the source does not name direct competitors 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Takeda bets on blockbuster drug trio to generate $11bn in peak salesNikkei Asia · 29 Oct 2026 · EN
- Takeda debuts narcolepsy drug targeting root cause, capping 15-year effortNikkei Asia · 27 Oct 2026 · EN
- Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?Yahoo Finance — News · 17 Sept 2026 · EN
- Former head of Takeda Pharmaceutical dies at 80The Japan Times · 11 Sept 2026 · EN
- Yasuchika Hasegawa, ex-Takeda CEO and globalization champion, dies at 80Nikkei Asia · 11 Sept 2026 · EN
- STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancerSTAT News · 30 Aug 2026 · EN
- Takeda aims for dengue vaccine inclusion in India's shots programNikkei Asia · 05 Aug 2026 · RO
- India approves its first dengue vaccine, from Japan's TakedaNikkei Asia · 21 Jul 2026 · RO
- Takeda marchează 245 de ani de tradiție japoneză, prin investiții în educație și sănătate în RomâniaMediafax · 07 Jul 2026 · RO
- Takeda signs US$600M AI drug discovery deal with InsilicoAI News · 03 Jul 2026 · EN
- Takeda and Insilico strike AI-led drug discovery deal worth up to $600mNikkei Asia · 02 Jul 2026 · RO
- Takeda's 1st female CEO leans into AI to shape biopharma businessNikkei Asia · 26 Jun 2026 · RO
- Takeda sees return to growth within three years, new CEO saysThe Japan Times · 26 Jun 2026 · RO
- Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. juryThe Japan Times · 19 May 2026 · RO
SEC filings
- Current report (foreign issuer)29 Oct 2026
- Current report (foreign issuer)29 Oct 2026
- Current report (foreign issuer)14 Sept 2026
- Current report (foreign issuer)31 Aug 2026
- Current report (foreign issuer)06 Aug 2026
- Current report (foreign issuer)30 Jul 2026
- Current report (foreign issuer)09 Jul 2026
- Current report (foreign issuer)08 Jul 2026
- Current report (foreign issuer)29 Jun 2026
- Current report (foreign issuer)26 Jun 2026
Sources
- [1] Form 20-F, fiscal year ended 2026-03-31 · SEC / Takeda Pharmaceutical Company Limited · 17 Jun 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.